We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+13.81%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.53B
AUM Growth
+$567M
Cap. Flow
+$2.93M
Cap. Flow %
0.04%
Top 10 Hldgs %
36.11%
Holding
184
New
8
Increased
71
Reduced
51
Closed
13

Top Buys

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$20.9M
2
INCY icon
Incyte
INCY
+$16.3M
3
ISRG icon
Intuitive Surgical
ISRG
+$14.4M
4
DXCM icon
DexCom
DXCM
+$14.1M
5
CNC icon
Centene
CNC
+$13.5M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$40.9M
2
UNH icon
UnitedHealth
UNH
+$38.4M
3
ELV icon
Elevance Health
ELV
+$26.9M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$24M
5
AXNX
Axonics, Inc. Common Stock
AXNX
+$19M

Sector Composition

Rank Sector Weight
1 Healthcare 99.55%
2 Industrials 0.38%
3 Energy 0.03%
4 Communication Services 0.01%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
1
Ionis Pharmaceuticals
IONS
$8.99B
$368M 4.88%
9,743,900
+280,500
+3% +$11.8M
ARGX icon
2
argenx
ARGX
$53.8B
$345M 4.58%
911,100
-8,246
-0.9% -$3.08M
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.2B
$331M 4.4%
2,773,294
-81,852
-3% -$9.59M
VRTX icon
4
Vertex Pharmaceuticals
VRTX
$123B
$317M 4.2%
1,096,028
-62,098
-5% -$18.9M
MRNA icon
5
Moderna
MRNA
$24.5B
$284M 3.77%
1,582,328
+22,527
+1% +$3.68M
ISRG icon
6
Intuitive Surgical
ISRG
$122B
$254M 3.37%
957,086
+58,994
+7% +$14.4M
INCY icon
7
Incyte
INCY
$23.4B
$238M 3.15%
2,956,977
+212,700
+8% +$16.3M
ALNY icon
8
Alnylam Pharmaceuticals
ALNY
$35.7B
$219M 2.91%
921,213
-35,549
-4% -$7.58M
ABT icon
9
Abbott
ABT
$175B
$185M 2.45%
1,684,479
+114,628
+7% +$11.9M
BSX icon
10
Boston Scientific
BSX
$65.4B
$181M 2.4%
3,902,924
+98,877
+3% +$4.28M
ITCI
11
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$177M 2.35%
3,342,236
+12,957
+0.4% +$649K
MYOV
12
DELISTED
Myovant Sciences Ltd.
MYOV
$159M 2.11%
5,910,639
-2,000
-0% -$52.6K
JAZZ icon
13
Jazz Pharmaceuticals
JAZZ
$15.5B
$121M 1.6%
756,636
-67,203
-8% -$9.85M
SYK icon
14
Stryker
SYK
$123B
$120M 1.6%
492,234
+15,302
+3% +$3.47M
AXNX
15
DELISTED
Axonics, Inc. Common Stock
AXNX
$119M 1.58%
1,906,461
-286,739
-13% -$19M
UNH icon
16
UnitedHealth
UNH
$387B
$119M 1.58%
224,294
-72,460
-24% -$38.4M
RVMD icon
17
Revolution Medicines
RVMD
$39.6B
$116M 1.53%
4,855,162
+175,000
+4% +$3.72M
AGIO icon
18
Agios Pharmaceuticals
AGIO
$2.36B
$114M 1.51%
4,056,792
-2,000
-0% -$56.4K
SAGE
19
DELISTED
Sage Therapeutics
SAGE
$113M 1.5%
2,969,278
-1,400
-0% -$53.5K
DXCM icon
20
DexCom
DXCM
$29.6B
$112M 1.49%
988,476
+128,016
+15% +$14.1M
PODD icon
21
Insulet
PODD
$11.4B
$102M 1.35%
345,780
-28,173
-8% -$7.77M
INSP icon
22
Inspire Medical Systems
INSP
$1.46B
$101M 1.34%
401,742
-26
-0% -$5.54K
DHR icon
23
Danaher
DHR
$144B
$97.2M 1.29%
413,243
-1,224
-0.3% -$284K
SRPT icon
24
Sarepta Therapeutics
SRPT
$1.82B
$89.8M 1.19%
693,209
-62,689
-8% -$7.26M
BDX icon
25
Becton Dickinson
BDX
$43.6B
$84.3M 1.12%
331,560
-3,278
-1% -$774K
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2022 Portfolio in Review

As of Q4 2022, Bellevue Group held 184 positions worth $7.53B, up 8.1% from $6.97B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Bellevue Group's Q4 2022 filing shows 8 new, 71 increased, 51 reduced and 13 closed positions. Its largest new stake was Natera: 173,812 shares worth $6.98M. The largest sale was Abiomed Inc, an estimated $40.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Industrials and Energy.

  • Bellevue Group's largest Q4 2022 buy was Natera: 173,812 shares worth $6.98M.
  • Bellevue Group added most to Fate Therapeutics in Q4 2022, an estimated $20.9M increase.
  • Bellevue Group's biggest Q4 2022 reduction was UnitedHealth, cutting an estimated $38.4M.
  • Bellevue Group fully exited Abiomed Inc in Q4 2022, selling an estimated $40.9M.
  • Bellevue Group's ten largest holdings make up 36% of its $7.53B portfolio in Q4 2022.
  • Bellevue Group opened 8 new positions and closed 13 in Q4 2022.
  • Bellevue Group's portfolio value rose 8.1% quarter-over-quarter to $7.53B.

Based on Bellevue Group's 13F filing for Q4 2022, filed 14 Feb 2023.